NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

T-Cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

Antigen-specific T cells CAR-T/CTL and DCvac

Antigen-specific T cells CAR-T/CTL and DCvac cells to treat T-ALL

Trial Locations (1)

RECRUITING

Shenzhen Geno-immune Medical Institute, Shenzhen

All Listed Sponsors

lead

Shenzhen Geno-Immune Medical Institute

OTHER